Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 14/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 13/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 13/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649667 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19226663 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL18431542 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL18993485 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19485353 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19302473 | 0.96 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21524575 | 0.96 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21166114 | 0.94 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL24908399 | 0.92 | GNAO1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21499826 | 0.91 | SIGMAR1 (0.38) | GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| US-7423154-B2 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7045625-B2 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20060074238-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| US-20040077861-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074238-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | SRM, SULT2A1, PNMT | GNAO1 3273/4885GNAI3 1712/4885GNAI1 1560/4885 |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, ABCB11, CEL | GNAO1 3970/4885GNAI3 1611/4885GNAI1 1773/4885 |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | GNAO1 1493/4885GNAI3 1813/4885GNAI1 1607/4885 |
| US-20040077861-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | SRM, SULT2A1, PNMT | GNAO1 3273/4885GNAI3 1712/4885GNAI1 1560/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | GNAO1 2346/4885GNAI3 2843/4885GNAI1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.